The sound of overhead explosions and bright flashes of light caused by fireworks. The sound of squealing tires followed by breaking glass. The smell of smoke and the sound of a smoke detector. The sound of the alarm on your oxygen concentrator in the middle of the night. Each of…
Medical trauma can trigger fierce post-traumatic stress disorder
The Phase 3 REBUILD clinical trial, which tested Bellerophon Therapeutics‘ inhaled nitric oxide therapy INOpulse in people with pulmonary fibrosis at risk of developing pulmonary hypertension, failed to meet its primary or secondary goals, according to recent top-line data. “The REBUILD study did not match the outcomes we…
When used in a real-world setting, Ofev (nintedanib) significantly prolonged the survival of idiopathic pulmonary fibrosis (IPF) patients, according to an analysis of Czech registry data. Yet, Ofev was not associated with a significant slowing of lung function decline or with other estimations of disease progression. Findings were…
I have learned a lot about idiopathic pulmonary fibrosis (IPF) over the years. Following my diagnosis in 2016, I read everything I could about this life-threatening lung disease through online forums, research articles, and various websites. My biggest takeaway was that disease progression is nonlinear and looks…
The calendar of any rare disease patient is a marvel, with its complexity and efficiency. I’ve become both a master and a failure in constructing mine. I continue to miss the mark on making time to live life to the fullest. My schedule gained new elements when I was…
Brilaroxazine, Reviva Pharmaceuticals’ experimental therapy for idiopathic pulmonary fibrosis (IPF), was found to reduce lung inflammation and fibrosis, or scarring, in a rat model of the disease. The treatment also improved lung function and extended survival in the animals, the study showed. Titled “Evaluation of Brilaroxazine (RP5063)…
Cumberland Pharmaceuticals is launching a Phase 2 clinical trial to assess the safety and efficacy of its investigational therapy, ifetroban, in treating patients with idiopathic pulmonary fibrosis (IPF). The announcement follows the U.S. Food and Drug Administration (FDA)…
My name is Sam, and I read a lot. I enjoy reading. I’m not asking for help or seeking an intervention. I read a wide variety of material and have favorites across many different genres. In the fiction category, I enjoy the Mitch Rapp series, originally by Vince Flynn. In…
Dosing is now complete in the Phase 2b GALACTIC-1 trial of GB0139 for treating idiopathic pulmonary fibrosis (IPF). The trial, which finished enrolling participants about a year ago, is testing the safety and effectiveness of the inhaled treatment candidate against a placebo among IPF patients who are…
An experimental oral medication Bristol Myers Squibb is developing did better than a placebo at slowing lung function decline for up to 26 weeks, slightly more than six months, in people with idiopathic pulmonary fibrosis (IPF). The effect was seen when the therapy, BMS-986278, was given at a…
